Veracyte, Inc.

{
  "main_header": {
    "sid": 1162410,
    "name": "Veracyte, Inc.",
    "stock_name": "Veracyte, Inc.",
    "full_name": "Veracyte, Inc.",
    "name_url": "stocks-analysis/veracyte-inc",
    "exchange": 1,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "40.57",
    "chg": 12.72,
    "chgp": "45.67%",
    "dir": 1,
    "prev_price": "27.85",
    "mcapval": "3,422.83",
    "mcap": "Small Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2325,
    "indexname": "S&P 500",
    "isin": "US92337F1075",
    "curr_date": "Jan 26",
    "curr_time": "",
    "bse_nse_vol": "730.15 k",
    "exc_status": "Active",
    "traded_date": "Jan 26, 2026",
    "traded_date_str": "2026 01 26",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/veracyte-inc-1162410-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Veracyte, Inc. Experiences Evaluation Adjustment Amid Competitive Market Landscape",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/veracyte-inc-sees-valuation-grade-shift-from-expensive-to-attractive-amid-price-increase-3667134",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/VeracyteInc_valuationdot_3667134.png",
        "date": "2025-11-03 16:00:21",
        "description": "Veracyte, Inc., a small-cap company in the Pharmaceuticals & Biotechnology sector, has adjusted its valuation, currently priced at $36.08. Over the past year, it has returned 6.94%, underperforming the S&P 500. Key metrics include a P/E ratio of 56 and a PEG ratio of 0.12, indicating potential growth."
      }
    ],
    "total": 18,
    "sid": "1162410",
    "stock_news_url": "https://www.marketsmojo.com/news/veracyte-inc-1162410"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Veracyte, Inc. Experiences Evaluation Adjustment Amid Competitive Market Landscape

2025-11-03 16:00:21

Veracyte, Inc., a small-cap company in the Pharmaceuticals & Biotechnology sector, has adjusted its valuation, currently priced at $36.08. Over the past year, it has returned 6.94%, underperforming the S&P 500. Key metrics include a P/E ratio of 56 and a PEG ratio of 0.12, indicating potential growth.

Read full news article

View All News